An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Trial Profile

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Abaloparatide (Primary) ; Alendronic acid
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational
  • Acronyms ACTIVExtend
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 02 Nov 2017 The Company expects to submit a labeling supplement to the FDA in connection with the ACTIVExtend results by the end of 2017, as reported in radius media relesae.
    • 10 Sep 2017 According to a Radius Health media release, results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2017.
    • 10 Aug 2017 Results published in a Radius Health Inc. Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top